Javascript must be enabled to continue!
Efficacy of lobectomy versus segmentectomy for congenital lung malformations: a systematic review and meta-analysis
View through CrossRef
Abstract
Background
Congenital lung malformations (CLMs) are uncommon anomalies characterized by a broad clinical spectrum, from asymptomatic cases to severe respiratory distress. Surgical resection is often indicated; nevertheless, the optimal extent of resection is still debated, especially regarding lobectomy versus lung-sparing segmentectomy.
Objective
This systematic review and meta-analysis aimed to compare the efficacy and safety of lobectomy versus segmentectomy in pediatric patients with CLMs.
Methods
We searched databases, including PubMed, Scopus, Web of Science, and Cochrane, to identify papers comparing lobectomy with segmentectomy in pediatric patients with CLMs. The main outcome was the duration of hospital stay (LOS). Secondary outcomes included operative time, chest tube removal duration, pulmonary function indices, and postoperative complications. Random-effects meta-analyses were applied.
Results
Nine retrospective observational studies involving infants and children were included. Meta-analysis showed no significant difference in LOS between lobectomy and segmentectomy (MD − 0.20, 95% CI − 0.83 to 0.44;
p
= 0.547). Operative time was significantly shorter with lobectomy (MD − 18.45, 95% CI − 27.21 to − 9.68;
p
< 0.0001). Chest tube removal time did not differ significantly between groups. Across all pulmonary function outcomes, no statistically significant differences were observed. Overall postoperative complications were similar between procedures (OR 0.96, 95% CI 0.58–1.61;
p
= 0.883).
Conclusions
Lobectomy and segmentectomy demonstrate no differences in hospital duration, complications, or pulmonary function; nevertheless, lobectomy provides a shorter surgical time and diminished early air leakage without affecting overall postoperative results. High-quality, prospective studies are essential for clarifying long-term outcomes to improve surgical decision-making.
Springer Science and Business Media LLC
Title: Efficacy of lobectomy versus segmentectomy for congenital lung malformations: a systematic review and meta-analysis
Description:
Abstract
Background
Congenital lung malformations (CLMs) are uncommon anomalies characterized by a broad clinical spectrum, from asymptomatic cases to severe respiratory distress.
Surgical resection is often indicated; nevertheless, the optimal extent of resection is still debated, especially regarding lobectomy versus lung-sparing segmentectomy.
Objective
This systematic review and meta-analysis aimed to compare the efficacy and safety of lobectomy versus segmentectomy in pediatric patients with CLMs.
Methods
We searched databases, including PubMed, Scopus, Web of Science, and Cochrane, to identify papers comparing lobectomy with segmentectomy in pediatric patients with CLMs.
The main outcome was the duration of hospital stay (LOS).
Secondary outcomes included operative time, chest tube removal duration, pulmonary function indices, and postoperative complications.
Random-effects meta-analyses were applied.
Results
Nine retrospective observational studies involving infants and children were included.
Meta-analysis showed no significant difference in LOS between lobectomy and segmentectomy (MD − 0.
20, 95% CI − 0.
83 to 0.
44;
p
= 0.
547).
Operative time was significantly shorter with lobectomy (MD − 18.
45, 95% CI − 27.
21 to − 9.
68;
p
< 0.
0001).
Chest tube removal time did not differ significantly between groups.
Across all pulmonary function outcomes, no statistically significant differences were observed.
Overall postoperative complications were similar between procedures (OR 0.
96, 95% CI 0.
58–1.
61;
p
= 0.
883).
Conclusions
Lobectomy and segmentectomy demonstrate no differences in hospital duration, complications, or pulmonary function; nevertheless, lobectomy provides a shorter surgical time and diminished early air leakage without affecting overall postoperative results.
High-quality, prospective studies are essential for clarifying long-term outcomes to improve surgical decision-making.
Related Results
Segmentectomies in patients with primary malignant lung tumors
Segmentectomies in patients with primary malignant lung tumors
Objective. To study the immediate and long-term outcomes of segmentectomy and lobectomy for malignant lung tumors. Material and methods. A retrospective study included patients wit...
Lung segmentectomy: does it offer a real functional benefit over lobectomy?
Lung segmentectomy: does it offer a real functional benefit over lobectomy?
Anatomical segmentectomy has been developed to offer better pulmonary function preservation than lobectomy, in stage IA lung cancer. Despite the retrospective nature of most of the...
Comparison of the Efficacy of SP-VATS Segmentectomy, SP-VATS Lobectomy, and 3P-VATS of Lobectomy in NSCLC Patients
Comparison of the Efficacy of SP-VATS Segmentectomy, SP-VATS Lobectomy, and 3P-VATS of Lobectomy in NSCLC Patients
Abstract
Objective: To analyze and study the clinical efficacy of single portal video-assisted thoracoscopic surgery (SP-VATS) segmentectomy, SP-VATS lobectomy, and convent...
Real-world outcomes of lobectomy, segmentectomy and wedge resection for the treatment of stage c-IA lung carcinoma
Real-world outcomes of lobectomy, segmentectomy and wedge resection for the treatment of stage c-IA lung carcinoma
Abstract
OBJECTIVES
To determine safety and survival outcomes associated with lobectomy, segmentectomy and wedge resection for e...
Outcomes of segmentectomy versus lobectomy in adults with non-cystic fibrosis bronchiectasis
Outcomes of segmentectomy versus lobectomy in adults with non-cystic fibrosis bronchiectasis
Objective: Surgical resection remains the gold standard treatment for bronchiectasis in patients who present with hemoptysis or suppuration, as well as in those who do not respond ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Hyalinizing Trabecular Tumor: A Case Series with Literature Review
Hyalinizing Trabecular Tumor: A Case Series with Literature Review
Abstract
Introduction: Hyalinizing trabecular tumor (HTT) is a rare thyroid neoplasm originating from follicular cells and poses diagnostic challenges due to its cytologic and hist...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...

